Rockwell Medical (RMTI)
NASDAQ:RMTI
Want to see RMTI full AI Analyst Report?
Top Page
Rockwell Med
(NASDAQ:RMTI)
Select Model
Select Model
Rating:51Neutral
Price Target:
$0.63
▼(-31.10% Downside)
Action:Reiterated
Date:06/16/26
The score is held back primarily by weak technicals (broadly below key moving averages with negative MACD) and uneven profitability/cash-flow consistency despite balance-sheet improvement. Constructive 2026 guidance and operational upgrades support the outlook, but listing-compliance risk and loss-driven valuation metrics keep overall risk elevated.
Positive Factors
Capacity Expansion (Automation)
Automating production to raise output ~50% materially lowers unit manufacturing costs and increases scalable capacity. Management estimates ~$3M incremental gross profit (≈$1.5M in 2026), a structural improvement that can sustainably boost gross margins and support larger contract volumes.
Negative Factors
Inconsistent Profitability
Return to losses and a TTM net margin near -9% show profitability remains fragile. This inconsistency undermines reliable free cash flow generation, raises execution risk for the turnaround, and limits the company’s ability to self-fund growth or absorb setbacks without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Capacity Expansion (Automation)
Automating production to raise output ~50% materially lowers unit manufacturing costs and increases scalable capacity. Management estimates ~$3M incremental gross profit (≈$1.5M in 2026), a structural improvement that can sustainably boost gross margins and support larger contract volumes.
Read all positive factors
Rockwell Med (RMTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.73M
Dividend YieldN/A
Average Volume (3M)334.66K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth-30.75%
EPS Growth-1056.69%
CountryUS
Employees244
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.15
Shares Outstanding39,470,300
10 Day Avg. Volume350,835
30 Day Avg. Volume334,658
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.81
Price to Sales (P/S)0.43
P/FCF Ratio-24.97
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue0.45
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda-11.74
Forecast
1Y Price Target
$3.00Price Target Upside229.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$72.47M
Rockwell Med Business Overview & Revenue Model
Company Description
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing ir...
How the Company Makes Money
Rockwell Medical makes money primarily by selling dialysis-related products to dialysis clinics and providers. The core revenue stream is the sale of dialysate concentrates (acid and bicarbonate concentrates) and other ancillary dialysis products,...
Rockwell Med Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call emphasized operational improvements (automation increasing capacity ~50%), margin expansion (gross margin +2 percentage points YoY), renewed contracts and an active customer pipeline, accompanied by concrete 2026 guidance (net sales $70–75M, gross margin 18–22%, adjusted EBITDA $1–2M, positive operating cash flow) and a clear plan to achieve positive net income in H2 2026. The primary negatives were a modest YoY revenue decline (-8% in Q1) driven by lower volumes from a prior large customer, a small Q1 net loss ($1.6M) and a slight decrease in cash due to seasonal items and a $0.5M acquisition payment. Overall, the positives around operational capacity increases, margin improvement, diversified customer base, and constructive guidance materially outweigh the modest near-term headwinds.Positive Updates
Strong Q1 Execution vs Expectations and 2026 Revenue Guidance
Net sales for Q1 2026 were $17.3 million (down 8% YoY) but exceeded internal expectations and track toward full-year guidance of $70 million to $75 million for 2026.
Negative Updates
Year-over-Year Revenue Decline
Net sales declined 8% versus Q1 2025. Management attributed the YoY decrease primarily to lower volumes from the company's then-largest customer.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Execution vs Expectations and 2026 Revenue Guidance
Net sales for Q1 2026 were $17.3 million (down 8% YoY) but exceeded internal expectations and track toward full-year guidance of $70 million to $75 million for 2026.
Read all positive updates
Company Guidance
Management guided 2026 annual results to net sales of $70–75 million, gross margin of 18%–22%, adjusted EBITDA of $1–2 million, positive operating cash flow (eliminating the need for additional capital) and a goal of positive net income in H2 2026 (subject to risks); they also reported Q1 2026 actuals of $17.3M net sales (−8% YoY), $2.9M gross profit, 17% gross margin (vs. 15% a year ago), $1.6M net loss (vs. $1.5M), adjusted EBITDA of −$0.3M (vs. −$0.4M), and $23.9M cash/investments (≈$1.1M decrease from $25M YE, including a $0.5M Evoqua payment); operational changes—two automated liquid lines expected to raise output ~50% and reduce cost per bottle—are estimated to add ~$3M of gross profit (about $1.5M realized in 2026), and longer-term targets by 2029 include >$100M net sales, gross margin approaching 30% and annual profitability of $5–10M.Rockwell Med Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.68M | 69.26M | 101.49M | 83.61M | 72.81M | 61.93M |
| Gross Profit | 11.55M | 11.70M | 17.48M | 8.70M | 4.08M | -2.42M |
| EBITDA | -2.59M | -2.00M | 2.95M | -4.69M | -16.17M | -27.80M |
| Net Income | -5.40M | -5.31M | -480.00K | -8.44M | -18.68M | -32.67M |
Balance Sheet | ||||||
| Total Assets | 57.42M | 57.15M | 59.21M | 52.17M | 46.63M | 48.57M |
| Cash, Cash Equivalents and Short-Term Investments | 23.89M | 25.00M | 21.60M | 10.94M | 21.49M | 22.44M |
| Total Debt | 14.39M | 12.47M | 13.54M | 13.44M | 16.36M | 28.89M |
| Total Liabilities | 21.57M | 20.16M | 26.62M | 30.88M | 32.53M | 46.04M |
| Stockholders Equity | 35.86M | 36.98M | 32.59M | 21.29M | 14.11M | 2.54M |
Cash Flow | ||||||
| Free Cash Flow | 1.76M | -1.20M | 3.19M | -9.70M | -17.21M | -34.06M |
| Operating Cash Flow | 2.66M | -659.00K | 4.20M | -9.41M | -16.93M | -33.53M |
| Investing Cash Flow | -8.66M | -8.54M | -4.87M | -3.04M | -2.40M | 311.00K |
| Financing Cash Flow | 4.22M | 4.25M | 7.35M | 11.34M | 16.15M | -2.18M |
Rockwell Med Technical Analysis
Negative
0.91
Price Trends
0.80
Negative
0.89
Negative
1.00
Negative
Market Momentum
-0.05
Negative
37.19
Neutral
54.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTI, the sentiment is Negative. The current price of 0.91 is above the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.80, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 37.19 is Neutral, neither overbought nor oversold. The STOCH value of 54.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RMTI.
Rockwell Med Risk Analysis
Rockwell Med disclosed 35 risk factors in its most recent earnings report. Rockwell Med reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rockwell Med Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $151.86M | -4.24 | -38.72% | ― | -14.15% | -15.69% | |
56 Neutral | $84.95M | -11.61 | -28.75% | ― | 2.08% | -106.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $26.73M | -4.74 | -15.41% | ― | -30.75% | -1056.69% | |
46 Neutral | $40.62M | -0.99 | -57.16% | ― | 673.54% | 23.14% | |
44 Neutral | $58.37M | -1.18 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
RMTI
Rockwell Med
0.64
-0.25
-28.09%
ASRT
Assertio Therapeutics
23.50
14.06
148.94%
SCYX
SCYNEXIS
4.05
-1.91
-32.00%
CPIX
Cumberland Pharmaceuticals
5.72
1.37
31.49%
KALA
KALA BIO
3.61
-208.39
-98.30%
Rockwell Med Corporate Events
Executive/Board ChangesShareholder MeetingsStock Split
Rockwell Medical Shareholders Approve Board, Pay and Reverse Split
Positive
Jun 15, 2026
At Rockwell Medical’s June 12, 2026 annual meeting, stockholders elected Class II directors Joseph Dawson and Joan Lau to new three-year terms expiring in 2029, maintaining continuity on the company’s board. Shareholders also gave advi...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Rockwell Medical Faces Nasdaq Compliance Challenge, Eyes Reverse Split
Negative
May 8, 2026
On May 8, 2026, Rockwell Medical, Inc. disclosed that it had received a notice from Nasdaq stating the company was no longer in compliance with the exchange’s $1.00 minimum bid price requirement, after its shares traded below that threshold ...
Business Operations and StrategyRegulatory Filings and Compliance
Rockwell Medical Issues Updated Investor Corporate Presentation
Neutral
May 7, 2026
On May 7, 2026, Rockwell Medical, Inc. made an updated corporate presentation available to investors and the broader market, signaling a refreshed communication of its strategy and performance outlook. The materials were furnished as part of a For...
Business Operations and StrategyRegulatory Filings and Compliance
Rockwell Med Updates Corporate Presentation for Investors
Neutral
Mar 26, 2026
On March 26, 2026, Rockwell Medical, Inc. released an updated corporate presentation to investors, making the materials publicly available through a regulatory filing. The update reflects the company’s ongoing effort to communicate its busin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.